Skip to content

Psychological and Electrophysiological Correlates of dementia with Lewy bodies and Parkinson's disease dementia

A randomised, repeated measures investigation of rhythmic auditory cues as a potential intervention for attentional fluctuations in dementia with Lewy bodies (DLB)/Parkinson's disease dementia (PDD)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN58368984
Enrollment
64
Registered
2006-09-15
Start date
2006-07-01
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia Nervous System Diseases Dementia

Interventions

Baseline versus rhythmic auditory cue versus rhythmic auditory cue at increased volume - a one-off assessment comparing patients baseline performance with performance under different experimental cond

Sponsors

King's College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Operationalised diagnosis of Dementia with Lewy Bodies (DLB), Parkinson?s Disease with Dementia (PDD), mild possible or probable Alzheimer?s Disease (AD), or Parkinson?s Disease (PD) 2. DLB and PDD patients must show clear signs of fluctuating cognition as indicated by a score eqaulling six on the One Day Fluctuation Assessment 3. Severity of dementia must be mild to moderate (Mini Mental State Examination [MMSE] greater than 14) 4. Capacity to give informed consent for participating in the study or Assent from Next of Kin (NOK) 5. Able to complete computerised test battery and understand instructions 6. Good hearing 7. Aged 63 - 89 years, either sex

Exclusion criteria

Exclusion criteria: 1. Symptoms or disabilities that would result in difficulties fulfilling the test requirements 2. Any diagnosis of another medical condition that in the eyes or the experimentor or investigator would prohibit partaking in the study 3. Ability to undergo 12 hour washout period from anti-parkinsonian medication before cognitive testing

Design outcomes

Primary

MeasureTime frame
Reaction time standard deviation, measured at intervention.

Secondary

MeasureTime frame
Measured at intervention: 1. Attentional performance 2. Reaction time 3. Tapping speed 4. Tracking precision 5. Electroencephalogram (EEG) mean frequency variability 6. Frequency of occurrence of stimulus independent thoughts

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026